Coherus BioSciences, Inc. Profile Avatar - Palmy Investing

Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the…

Biotechnology
US, Redwood City [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Coherus BioSciences, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CHRS's Analysis
CIK: 1512762 CUSIP: 19249H103 ISIN: US19249H1032 LEI: - UEI: -
Secondary Listings
CHRS has no secondary listings inside our databases.